Skip to main content
. Author manuscript; available in PMC: 2016 Oct 1.
Published in final edited form as: Mol Cancer Ther. 2015 Jul 23;14(10):2249–2259. doi: 10.1158/1535-7163.MCT-15-0429

Figure 6. In vivo activity of CGM097 in p53 wt patient-derived AML xenograft.

Figure 6

(A) Tumor growth curves of a patient-derived p53 wt AML xenogfraft treated with CGM097 or ARA-C (standard of care control). Treatment with CGM097 was initiated on day 35 post-implantation, when tumor burden reached 18% (measured by % hCD45+ cells), and continued until day 69 when tumor burden in the untreated group reached 87%. CGM097 significantly reduced in vivo tumor growth (P = 0.0004 by two-tailed unpaired Student's t test). Treatment with ARA-C was initiated on day 35 post implantation, and stopped on day 50 due to body weight loss in all treated mice. Error bars represent S.E.M. (B) Percent body weight change in mice following treatment. CGM097 dosed at 100mg/kg po qd for 34 days was well-tolerated with no significant body weight changes. ARA-C dosed at 50 mg/kg ip qd for 15 days was not well-tolerated and all mice were sacrificed on day 50 post tumor implantation. Error bars represent S.E.M. AML model details: HAMLX5340: FLT3-ITD; NPM1 mut; p53WT.